Bunazosin
From Wikipedia, the free encyclopedia
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | none |
Identifiers | |
|
|
CAS Number | 80755-51-7 |
PubChem (CID) | 2472 |
ChemSpider | 2378 |
UNII | 9UUW4V7G2H |
ChEMBL | CHEMBL188185 |
Chemical and physical data | |
Formula | C19H27N5O3 |
Molar mass | 373.44 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
(verify) |
Bunazosin (INN) is an alpha 1 antagonist. Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH). It has been approved in Japan in a topical form to treat glaucoma. The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. It also may act to improve blood flow to the ocular nerve. Systemic Alpha-1 adrenergic receptor antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS). Bunazosin potentially could have the same effect but there has been no research to substantiate this as a risk for cataract surgery.
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |